I'm LongbridgeAI, I can summarize articles.Leerink Partners maintains an Outperform rating on CVS Health with a $112 price target, implying 30% upside from the Oct 9 close. The firm cites CVS's strong integrated healthcare model and resilient financial outlook despite headwinds like the 340B program and Medicare Advantage pressures. Analysts view the stock as undervalued due to stable cash flow and improved margins.
Leerink Partners maintained their Outperform rating on CVS Health's stock with a price target of $112.00.
The price target implies an upside of 30.0% from the Oct 9 close of $86.16.
Key takeaways from the analyst note
Strong Integrated Healthcare Model: CVS Health's diversified business segments—retail pharmacy, pharmacy benefit management (PBM), health insurance, and primary care services—create synergies that position the company for long-term growth in a rapidly evolving healthcare landscape.
Positive Financial Outlook despite Challenges: Despite facing some headwinds, including pressures from the 340B program and Medicare Advantage, CVS has demonstrated resilience with stable cash flow generation and improved margins, leading analysts to believe the stock is undervalued with a price target set at $112.00.
Explore more price target data and ratings for CVS Health on the .